midazolam has been researched along with Blood Diseases in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam and ketamine were administered consecutively by intravenous route under cardiorespiratory monitoring for painful procedures of pediatric hematology." | 3.81 | The Efficacy and Safety of Procedural Sedoanalgesia with Midazolam and Ketamine in Pediatric Hematology. ( Çakmak, E; Demirsoy, U; Gelen, SA; Sarper, N; Zengin, E, 2015) |
| " Dosing of major CYP3A substrate drugs needs to be reduced in palliative patients with haematological diseases, otherwise escalation of debilitating symptoms due to drug interactions might occur." | 2.90 | Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies. ( Bardenheuer, H; Burhenne, J; Egerer, G; Geist, MJP; Mikus, G; Siller, N, 2019) |
| " Procedure and recovery time were correlated to ketamine dosage (p <." | 1.32 | Sedation with midazolam and ketamine for invasive procedures in children with malignancies and hematological disorders: a prospective study with reference to the sympathomimetic properties of ketamine. ( Aliani, S; Gottschling, S; Graf, N; Meyer, S; Reinhard, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geist, MJP | 1 |
| Siller, N | 1 |
| Egerer, G | 1 |
| Bardenheuer, H | 1 |
| Burhenne, J | 1 |
| Mikus, G | 1 |
| Gelen, SA | 1 |
| Sarper, N | 1 |
| Demirsoy, U | 1 |
| Zengin, E | 1 |
| Çakmak, E | 1 |
| Meyer, S | 1 |
| Aliani, S | 1 |
| Graf, N | 1 |
| Reinhard, H | 1 |
| Gottschling, S | 1 |
1 trial available for midazolam and Blood Diseases
| Article | Year |
|---|---|
Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biological Variation, Population; Case-Control | 2019 |
2 other studies available for midazolam and Blood Diseases
| Article | Year |
|---|---|
The Efficacy and Safety of Procedural Sedoanalgesia with Midazolam and Ketamine in Pediatric Hematology.
Topics: Adolescent; Analgesia; Analgesics; Bone Marrow Examination; Child; Child, Preschool; Deep Sedation; | 2015 |
Sedation with midazolam and ketamine for invasive procedures in children with malignancies and hematological disorders: a prospective study with reference to the sympathomimetic properties of ketamine.
Topics: Anesthetics, Combined; Anesthetics, Dissociative; Anesthetics, Intravenous; Child; Conscious Sedatio | 2003 |